drugset / Trial / NCT06335355
A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
Evaluating the Efficacy and safety of Adebrelimab in Combination with Platinum-based Doublet Chemotherapy and SHR-8068 as First-line Therapy for Patients with Advanced or Metastatic NSCLC Carrying STK11/KEAP1/KRAS Mutations
Timeline
- Start
- 2024-03
- Primary completion
- 2028-10
- Completion
- 2030-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | 1200 mg | — |
| Comparator | Camrelizumab | Monoclonal antibody | 200 mg | — |
| Subject | SHR-8068 | Monoclonal antibody | 1 mg/kg | — |
| Background | Carboplatin | Small molecule | 5 unknown | — |
| Background | Pemetrexed | Small molecule | 500 mg/m2 | — |